FDA Approves Lipfendra, an Oral PCSK9 Inhibitor for Cholesterol

The briefing

Merck said the FDA has approved Lipfendra, a cholesterol-lowering pill that works as a PCSK9 inhibitor. The new oral option could expand treatment choices for patients who need additional LDL reduction beyond existing therapies.